Statin use does not prevent the occurrence of Alzheimer's disease,

2008 ◽  
Vol &NA; (1622) ◽  
pp. 18
Author(s):  
&NA;
2010 ◽  
Vol 58 (7) ◽  
pp. 1311-1317 ◽  
Author(s):  
Ge Li ◽  
Jane B. Shofer ◽  
Isaac C. Rhew ◽  
Walter A. Kukull ◽  
Elaine R. Peskind ◽  
...  

2020 ◽  
Vol 75 (3) ◽  
pp. 903-910
Author(s):  
Tonita Wroolie ◽  
Siena Roat-Shumway ◽  
Katie Watson ◽  
Eric Reiman ◽  
Natalie Rasgon

2007 ◽  
Vol 3 (3S_Part_3) ◽  
pp. S192-S192
Author(s):  
Warren B. Zigman ◽  
Nicole Schupf ◽  
Edmund C. Jenkins ◽  
Tiina K. Urv ◽  
Benjamin Tycko ◽  
...  

2006 ◽  
Vol 2 (2) ◽  
pp. 96-103 ◽  
Author(s):  
Robert C. Green ◽  
Sally E. McNagny ◽  
Parimala Jayakumar ◽  
L. Adrienne Cupples ◽  
Kelly Benke ◽  
...  

2007 ◽  
Vol 416 (3) ◽  
pp. 279-284 ◽  
Author(s):  
Warren B. Zigman ◽  
Nicole Schupf ◽  
Edmund C. Jenkins ◽  
Tiina K. Urv ◽  
Benjamin Tycko ◽  
...  

2021 ◽  
Vol 11 (3) ◽  
pp. 396
Author(s):  
Ji Hee Kim ◽  
Heui Seung Lee ◽  
Jee Hye Wee ◽  
Yoo Hwan Kim ◽  
Chan Yang Min ◽  
...  

A number of studies report the incidence of Alzheimer’s disease (AD) in patients taking statins, but the results are inconsistent. (1) Background: The present study investigated the cross-sectional association between previous statin use and the risk of AD development in Korean residents. (2) Methods: We used the Korean National Health Insurance Service-National Sample Cohort; 17,172 AD patients were matched by age, gender, income, and region of residence with 68,688 control participants at a ratio of 1:4. We used a multiple conditional logistic regression model to analyse the association between the number of days of statin use and AD occurrence. Further analyses were performed to identify whether this association is maintained for different ages, genders, socioeconomic status groups, and covariates. (3) Results: The odds ratio, which was adjusted for potential confounders, for the days of statin use per year in the AD group compared to the control group was 0.95 (95% confidence interval = 0.92–0.98; p = 0.003). The number of days of statin use in the AD group was significantly smaller in the subgroups of non-smokers and individuals with normal weight, alcohol consumption less than once a week, total cholesterol level below 200 mg/dL, systolic blood pressure below 140, diastolic blood pressure below 90, and fasting blood glucose below 100 mg/dL. (4) Conclusions: Our results suggest that statin use prevents the occurrence of AD. The effects of statin use in preventing AD may be greater in individuals at relatively low risk.


2020 ◽  
Author(s):  
Arianna Dagliati ◽  
Niels Peek ◽  
Roberta Diaz Brinton ◽  
Nophar Geifman

Abstract Background. Significant evidence suggests that the cholesterol-lowering statins can effect cognitive function, and reduce the risk for Alzheimer’s disease and dementia. These potential effects may be constrained by specific combinations of an individual’s sex and Apolipoprotein E (APOE) genotype. Methods. Here we examine data from 252,327 UK BioBank participants, aged 55 or over, and compare the effects of statin use in males and females. We identified that in this population, males were older, had a higher level of education, better cognitive scores, higher incidence of cardiovascular and metabolic diseases, and a higher rate of statin use.Results. We observed that males and those participants with an APOE4 (E4 variant of APOE) positive genotype had higher probabilities of being treated with statins; while participants with an Alzheimer’s diagnosis had slightly lower probabilities. We found that use of statins was not significantly associated with overall higher rates of survival. However, when considering the interaction of statin use with sex, the results suggest higher survival rates in males treated with statins. Finally, examination of cognitive function indicates a potential beneficial effect of statins, however this is limited to APOE4 positive genotypes. Conclusions. Our evaluation of the ageing population in a large cohort from the UK BioBank confirms sex and APOE genotype as funda mental risk stratifiers for Alzheimer’s disease and cognitive function, furthermore it extends them to the specific area of statin use, clarifying their specific interactions with treatments.


2004 ◽  
Vol 23 (1-2) ◽  
pp. 94-98 ◽  
Author(s):  
Edward Zamrini ◽  
Gerald McGwin ◽  
Jeffrey M. Roseman

Sign in / Sign up

Export Citation Format

Share Document